| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The compound targets the same biological pathways as unlabeled L-cysteine, including the transsulfuration pathway, cysteine transport system, and glutathione biosynthesis. It is incorporated into proteins and serves as a carbon backbone donor for various metabolites.
|
|---|---|
| ln Vitro |
In cell culture, L-Cysteine-1-13C is used as a tracer to track carbon incorporation into products like glutathione, taurine, pyruvate, and CO2. It is particularly useful for studying the metabolic fate of cysteine carbon atoms in cancer cells and other models of altered metabolism.
|
| ln Vivo |
The compound is administered to animals (e.g., rodents) or humans via intravenous tracer infusion to study whole-body cysteine kinetics, including plasma flux, oxidation rate, and glutathione synthesis rates. The position of the ¹3C label allows for tracking of carbon atom fate.
|
| Enzyme Assay |
Non-cell assays involve incubating the labeled compound with purified enzymes (e.g., cysteine dioxygenase) or tissue homogenates. The ¹3C label enables tracking of the carboxyl carbon's fate in downstream products (e.g., ¹3CO2, ¹3C-labeled pyruvate) by LC-MS or GC-MS.
|
| Cell Assay |
Primary cells (e.g., hepatocytes) or cancer cell lines are cultured in custom medium containing L-Cysteine-1-13C. After incubation for various times, cells are lysed and metabolites extracted. ¹3C enrichment in metabolites is analyzed by LC-MS or NMR to determine carbon flux through various pathways.
|
| Animal Protocol |
In animal studies, L-Cysteine-1-13C is typically administered to rodents via intravenous infusion (primed constant infusion over 6 hours) or intraperitoneal injection. Blood and tissue samples are collected to measure isotopic enrichment of plasma cysteine and glutathione by gas chromatography-mass spectrometry.
|
| ADME/Pharmacokinetics |
The pharmacokinetics are identical to unlabeled L-cysteine. The ¹3C label does not alter absorption, distribution, metabolism, or excretion. It is metabolized to glutathione, taurine, H2S, and oxidized to CO2 via cysteine dioxygenase. The ¹3CO2 produced can be measured in exhaled breath.
|
| Toxicity/Toxicokinetics |
L-Cysteine is generally recognized as safe (GRAS). High doses may be neurotoxic and nephrotoxic in animal models. The labeled analog is considered safe for research use at tracer doses (mg/kg levels). The LD₅0 is comparable to unlabeled cysteine (~1.9 g/kg in rats).
|
| References | |
| Additional Infomation |
This compound is not a drug but a research tool. It is widely used in metabolic flux analysis, tracing cysteine carbon atoms in disease models (cancer, diabetes, neurodegeneration), and as an internal standard for LC-MS/MS quantification of cysteine in biological samples. It has been used in human studies of sepsis.
|
| Molecular Formula |
C213CH7NO2S
|
|---|---|
| Molecular Weight |
122.15
|
| Exact Mass |
121.019
|
| CAS # |
224054-24-4
|
| Related CAS # |
L-Cysteine;52-90-4
|
| PubChem CID |
71309363
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
293.9±35.0 °C at 760 mmHg
|
| Flash Point |
131.5±25.9 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.550
|
| LogP |
0.23
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
7
|
| Complexity |
75.3
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C([C@@H]([13C](=O)O)N)S
|
| InChi Key |
XUJNEKJLAYXESH-NSQKCYGPSA-N
|
| InChi Code |
InChI=1S/C3H7NO2S/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1/i3+1
|
| Chemical Name |
(2R)-2-amino-3-sulfanyl(113C)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.1867 mL | 40.9333 mL | 81.8666 mL | |
| 5 mM | 1.6373 mL | 8.1867 mL | 16.3733 mL | |
| 10 mM | 0.8187 mL | 4.0933 mL | 8.1867 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
